Ruijian Pharma Scoops up ￥100 Million in Series A Financing

(VCBeat) Aug. 11, 2021 -- Wuhan Ruijian Pharmaceutical Technology Co., Ltd. ("Ruijian Pharma"), which has been established for four years, today announced that it raised nearly 100 million yuan in a Series A funding round, led by Fortune Venture Capital with participation from Jiuyo Capital.

The funds are earmarked for the Phase I clinical trial of NouvNeu001, Ruijian Pharma's first pipeline for the treatment of Parkinson's disease under development. Ruijian Pharma has also moved to a new R&D and production base with a total area of 4,000 square meters, and completed the company's facility and hardware upgrading, and will start pilot production of several new pipelines in the newly constructed "B+A" level pilot workshop.

Ruijian Pharma is the world's first high-tech pharmaceutical company focusing on the research of efficient small molecules inducing functional cell regeneration. At present, focusing on the research and transformation of the mechanism for cell fate regulation, Ruijian Pharma has built a drug research and development technology platform based on small molecule-induced cellular conversion, and has carried out a comprehensive and systematic patent layout.

Founded in April 2000, Fortune Capital is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focuses its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.

Fortune Capital is ranked among the highest-performing VC/PE firms in China. In addition to providing capital, Fortune Capital provides its investee companies with personalized value-added services.

Founded by more than 100 partners with financial and industrial background, Jiuyo Capital is an equity investment firm. The company has three main business segments: investment management, FA services, and financial consulting. 

Jiuyo Capital mainly invests in the field of AI technology, communication technology, new materials, advanced manufacturing, innovative drugs, and precision medicine.